CareDx enters agreement with Stanford to seek Supreme Court review of patent validity; royalties suspended

CareDx, Inc.

Agreement dated March 29, 2023, effective Feb 3, 2023, with Stanford to seek Supreme Court review of Federal Circuit patent decision.
Royalty payment and reporting obligations on U.S. licensed products suspended during pendency of Supreme Court review.
Company's 30-day termination right under exclusive license agreement is also suspended during review.
Agreement modifies post-termination obligations and allocation of legal fees between the parties.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CareDx, Inc. amended Agreement Regarding Payment of Royalties and Amendment to the Amended and Restated Exclusive License Agreement with Stanford University (effective 2023-02-03).

Action: amendment
Agreement: license
Counterparty: Stanford University
Effective: 2023-02-03

Exact text from the filing

On March 29, 2023, the Parties entered into an Agreement Regarding Payment of Royalties and Amendment to the Amended and Restated Exclusive License Agreement (the “Agreement and Amendment”).

View on SEC.gov

Browse all material agreements →

CareDx, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-088888

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.